Document:

EX-10.16

 Exhibit 10.16 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 LICENSE AGREEMENT 

University of Michigan File 4774 and 5424 
 This
License Agreement (“Agreement”) is effective as of 22 January, 2013 (the “Effective Date”), between GenomeDx Biosciences, Inc. (“LICENSEE”) having the address in Article 13 below, and the Regents of the University
of Michigan, a constitutional corporation of the state of Michigan (“MICHIGAN”). LICENSEE and MICHIGAN agree as follows: 

ARTICLE 1 — DEFINITIONS 
 1.1
        “AFFILIATE” means any individual, corporation, firm, partnership or other entity, which directly or indirectly owns, is owned by, or is under common ownership with LICENSEE to the extent of
at least fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction), having the power to vote on or direct the affairs of the entity and any person,
firm, partnership, corporation or other entity actually controlled by, controlling, or under common control with LICENSEE through equity ownership, ability to elect directors, or by virtue of a majority of overlapping directors. 

1.2         “CO-EXCLUSIVE FIELD OF USE” means diagnostic tests
formatted for urine and blood samples. 
 1.3 “EXCLUSIVE FIELD OF USE” means diagnostic tests for all uses (including but not limited to disease
screening, detection and selection of patients for treatment) except those in CO-EXCLUSIVE FIELD OF USE. 
 1.4
        “FIRST COMMERCIAL SALE” means, with respect to a LICENSED PRODUCT, the first sale of such LICENSED PRODUCT by LICENSEE, its AFFILIATE or a SUBLICENSEE to a third party after regulatory
approval has been obtained therefor, other than sale of a LICENSED PRODUCT for use in trials, such as field trials or clinical trials, being conducted to obtain FDA or other governmental approvals to market LICENSED PRODUCTS. 

1.5         “LICENSED PROCESS(ES)” means performing services for a fee, using the LICENSED PRODUCT. 

1.6         “LICENSED PRODUCT(S)” means any product or process that in the making, using, importing,
exporting or selling of such product or process would, absent the license granted under this Agreement, infringe a VALID CLAIM of PATENT RIGHTS. 
 1.7
        “NET SALES” means the amount received by LICENSEE, its AFFILIATE or any SUBLICENSEE, on sales by LICENSEE, its AFFILIATE or any SUBLICENSEE of a LICENSED PRODUCT or LICENSED PROCESS to a
third party less documented: 
 (a) duties, import, export, sales, excise or use taxes or other government charges; 

(b) credits for defective or returned LICENSED PRODUCTS or LICENSED PROCESSES actually given; 

 

 (c) regular trade discount allowances, incentives, rebates, or price reductions actually
given; 
 (d) transportation, handling and distribution costs for such LICENSED PRODUCT or LICENSED PROCESS; and 

(e) costs associated with collecting, shipping and pathology work conducted on the samples relating to the LICENSED PROCESSES. 

NET SALES shall not include any amount for: the transfer of LICENSED PRODUCT as samples, for marketing purposes or on compassionate grounds and, prior to the
receipt of regulatory approval therefor, trial materials, and the sale or other transfer of LICENSED PRODUCT between LICENSEE and any of its AFFILIATES or between such AFFILIATES, provided that any subsequent resale or
re-transfer of such LICENSED PRODUCT to a third party end user of the LICENSED PRODUCT shall be included in NET SALES. NET SALES shall be determined from the books and records of LICENSEE and/or its AFFILIATES
maintained in accordance with U.S. generally accepted accounting principles consistently applied. 
 Where LICENSEE receives any consideration other than
cash for such transactions, fair market cash value (at the time of the transaction) for such consideration, to be agreed upon by the parties hereto, shall be included in NET SALES. 

NET SALES for a particular LICENSED PRODUCT will be calculated by multiplying the total revenue received for such LICENSED PRODUCT with a factor
(“MULTI-GENE PRODUCT FACTOR”) that reflects the relative contribution of the MICHIGAN licensed technology in such LICENSED PRODUCT, based on the percentage of biomarkers configured in such LICENSED PRODUCT that are claimed by a VALID CLAIM
of PATENT RIGHTS and calculated as set forth below. 
 The MULTI-GENE PRODUCT FACTOR shall be A/B, where A is equal to the sum of the number of biomarkers
claimed by a VALID CLAIM of PATENT RIGHTS, and B is equal to the sum of the total number of biomarkers included in such LICENSED PRODUCT. 
 1.8
        “PATENT RIGHTS” means all of MICHIGAN’S legal rights under the patent laws of the United States or relevant foreign countries for all of the following: 

(a) the following United States and foreign patent(s) and/or patent application(s), and any divisionals, continuations and continuations-in-part (but only to the extent that such claims in continuation in part applications are directed to subject matter specifically described in the foregoing
patents and/or patent applications), and any foreign counterparts of the same: 
 [***] 

and 

  

					
		  		  	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
		  	2	  	

 all patent applications which claim inventions disclosed prior to the Effective Date to the
MICHIGAN Office of Technology Transfer and specifically described and enabled in the following Office of Technology Transfer files: 4774 and 5424. 

(b) Any and all United States and foreign patents issued from the applications listed in subparagraph 1.6(a) above, including any
substitution, reissued or reexamined patents based upon the same. 
 1.9         “ROYALTY PERIOD(S)”
means, with respect to the ROYALTY TERM, the six (6) month periods of each calendar year, ending on the last days of June and December, 
 1.10
“ROYALTY TERM” means, on LICENSED PRODUCT-by-LICENSED PRODUCT and
country-by-country basis for a particular LICENSED PRODUCT in a particular country, the period beginning on the FIRST COMMERCIAL SALE of such LICENSED PRODUCT in such
country and ending upon the date of expiration of the last VALID CLAIM in the PATENT RIGHTS claiming the composition of matter or method of making or using such LICENSED PRODUCT in such country, 

1.11         “SUBLICENSEE(S)” means any third party person or entity granted a sublicense by LICENSEE under
the license grant to LICENSEE in Section 2.1 of this Agreement. 
 1.12         “TERRITORY” means
worldwide. 
 1.13         “VALID CLAIM” means a claim contained in (a) an issued and unexpired
patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to
be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise, or (b) a patent application that has not been irretrievably cancelled, withdrawn or abandoned and that has been pending for less than [***] years from the filing
date from which such claim takes priority; provided, however, it shall exclude any claim that is subject to a then-ongoing interference proceeding or any claim in a patent application or issued patent that has been lost as a result of an
interference proceeding. 
 ARTICLE 2 — GRANT OF LICENSE 

2.1         Subject to the terms and conditions of this Agreement, MICHIGAN hereby grants to LICENSEE an exclusive
license under the PATENT RIGHTS, in the EXCLUSIVE FIELD OF USE and a co-exclusive license in the CO-EXCLUSIVE FIELD OF USE, both such licenses with the right to grant
sublicenses through multiple tiers and the TERRITORY to research, develop, make, have made, import, use, market, offer for sale and sell LICENSED PRODUCTS and to practice LICENSED PROCESSES. 

2.2         MICHIGAN agrees that, during the first five years from the Effective Date, it will not discuss, enter into
negotiations for, or grant to any Third Party a license under Co-Exclusive Patent Rights, without first offering the right to LICENSEE to obtain such rights by providing written notification to LICENSEE.
Within [***] days after receiving such notification, LICENSEE shall notify MICHIGAN in writing as to whether it desires to obtain a license under 

  

					
		  		  	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
		  	3	  	

 
such inventions (the “Notification Period”). In the event LICENSEE does not notify MICHIGAN of its desire to obtain such license by the end of the Notification Period, or if LICENSEE
provides MICHIGAN with written notification at any time prior to the end of the Notification Period that it does not wish to obtain such license, then MICHIGAN shall have the right to provide such license to a Third Party without further obligation
to LICENSEE. If LICENSEE notifies MICHIGAN of its desire to obtain such license within such Notification Period, then, promptly after MICHIGAN’s receipt of LICENSEE’s notification, the Parties shall negotiate in good faith, for a period of
[***] months after MICHIGAN’s receipt of such notice (the “Negotiation Period”), an amendment to this License Agreement governing the terms and conditions under which LICENSEE would obtain such expanded rights. In the event the
Parties, despite good faith negotiations, are unable to enter into such agreement within such Negotiation Period, then MICHIGAN shall have the right to grant rights to the invention to a Third Party on terms that, taken as a whole, are no more
favorable to MICHIGAN than those last offered by LICENSEE. 
 2.3         Without limiting any other rights it may
have, MICHIGAN specifically reserves the right to practice the PATENT RIGHTS for its internal non-commercial research (i.e., not sponsored research for or collaboration with
for-profit entities), public service, and/or educational purposes, and the right to grant the same limited rights to other non-profit research institutions. MICHIGAN and
the University of Michigan Health Systems shall have the retained right to practice PATENT RIGHT(S) in the FIELD(S) of USE for activities involving patient care of MICHIGAN’s own patients (including fee-for-service diagnostic testing for such patients) and shall not perform services for any patient at any hospital or clinic that is not part of MICHIGAN or the University of Michigan Health System. 

2.4         The term of this Agreement shall commence on the Effective Date and continue until expiration of the last
to expire ROYALTY TERM, unless sooner terminated as provided in another specific article of this Agreement. Upon expiration of the term of this Agreement, the license granted to LICENSEE under Section 2.1 shall become a fully paid-up, perpetual, irrevocable license. 
 2.5         LICENSEE agrees that
LICENSED PRODUCTS used, leased or sold in the United States shall be manufactured substantially in the United States. At LICENSEE’s request, MICHIGAN will request a waiver of this requirement from the Federal funding agency and LICENSEE shall
cooperate with MICHIGAN and provide all requested information in support of such waiver application. 
 2.6
        The licenses granted in this Agreement are subject to any rights required to be retained by the U.S. government, for example in accordance with Chapter 18 of Title 35 of U.S.C. 200-212 and the regulations thereunder (37 CFR Part 401), when applicable. LICENSEE agrees to comply in all material respects, and shall provide MICHIGAN with all reasonably requested information and cooperation for
MICHIGAN to comply with applicable provisions of the same and any requirements of any contracts between MICHIGAN and any agency of the U.S. government that provided funding for the subject matter covered by the PATENT RIGHTS. 

2.7         LICENSEE acknowledges that it has been informed that the licensed PATENT RIGHTS were developed, at least
in part, by employees of the Howard Hughes Medical Institute (“HHMI”) and that HHMI has a paid-up, non-exclusive, irrevocable license to use the licensed

  

					
		  		  	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
		  	4	  	

 
PATENT RIGHTS for HHMI’s research purposes, but with no right to assign or sublicense (the “HHMI License”). This license is explicitly made subject to the HHMI License. 

ARTICLE 3 — CONSIDERATION 
 3.1
        LICENSEE shall pay the following fees and royalties to MICHIGAN during the term of this Agreement. The fees and royalties shall be: 

(a) A one-time upfront license issue fee equal to Fifty Thousand Dollars ($50,000). Such license issue
fee shall be nonrefundable and is due thirty days (30) after the Effective Date. LICENSEE will pay further fees in the form of reimbursement of certain costs pursuant to Article 7 hereof. 

(b) During the ROYALTY TERM, on a LICENSED PRODUCT-by-LICENSED
PRODUCT basis, running royalties based on NET SALES of a LICENSED PRODUCT as follows: 
 For that portion of annual NET SALES of such
LICENSED PRODUCT that are less than or equal to [***] Dollars ($[***]): [***] percent ([***]%); and 
 For that portion of annual NET SALES
of such LICENSED PRODUCT that are in excess of [***] Dollars ($[***]): [***] percent ([***]%). 
 During the term of the Agreement, in the
absence of a VALID CLAIM of the PATENT RIGHTS claiming the composition of matter or method of making or using such LICENSED PRODUCT, LICENSEE shall pay a royalty of [***] percent ([***]%) of NET SALES in the country of manufacture or sale as
conducted by LICENSEE for the first seven (7) years after FIRST COMMERCIAL SALE of such LICENSED PRODUCT. 
 (c) If LICENSEE or its
AFFILIATE is obligated or reasonably deems it necessary to pay consideration to any third party that holds any intellectual property rights that would, in the reasonable judgment of LICENSEE be infringed by the manufacture, importation, use, offer
for sale or sale of a LICENSED PRODUCT, then LICENSEE shall be entitled to deduct [***] percent ([***]%) of such consideration paid to such third party from the royalties payable to MICHIGAN under Section 3.1(b). However, in no event shall the
royalties payable to MICHIGAN under Section 3.1(b) for any ROYALTY PERIOD be reduced pursuant to this Section 3.1(c) to less than [***] of the rates otherwise owed to MICHIGAN. LICENSEE shall notify MICHIGAN of the execution of any
agreement with a third party that triggers the royalty reduction referred to in this Section 3.1(c) and the applicable royalty rates therefore. 

(d) In consideration of the license granted hereunder LICENSEE will make, without duplication, in respect of any LICENSED PRODUCT,
nonrefundable and non- creditable payments to MICHIGAN of [***] percent ([***]%) of sublicense fees received by LICENSEE and directly attributable to a sublicense granted

  

					
		  		  	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
		  	5	  	

 hereunder, that is received by LICENSEE, until the date of expiration of the last ROYALTY
TERM for such LICENSED PRODUCT in the country of manufacture or sale as conducted by the SUBLICENSEE as applicable. Such sublicense fees do not include royalties received by LICENSEE or payments received by LICENSEE specifically purposed for
LICENSEE’s products or services such as research, development, manufacturing, commercialization or patent prosecution, and would include any payment received by LICENSEE in exchange for LICENSEE’s equity only to the extent such payment
amount exceeds the fair market value of such equity at the time of the transaction. 
 (e) Within thirty (30) days of receipt after an
invoice from MICHIGAN, LICENSEE shall reimburse MICHIGAN for documented third party patent costs associated with the PATENT RIGHTS incurred by MICHIGAN prior to the Effective date, in an amount not to exceed [***] Dollars ($[***]). 

(f) LICENSEE shall pay to MICHIGAN the following minimum annual royalties (“Annual Fee”). This Annual Fee is accrued on June 30
of the years specified below. LICENSEE may credit each Annual Fee in full against all royalties under subsections (b) and (d) above otherwise due MICHIGAN for the prior July 1 through the June 30 on which the Annual Fee accrues. The
Annual Fees are: 
  

	 	(1)	 First Annual Fee beginning on June 30, 2014 and each Annual Fee thereafter until the FIRST COMMERCIAL SALE
of the first LICENSED PRODUCT: Ten Thousand Dollars ($10,000). Each such Annual Fee is payable with the annual report in which the Annual Fee accrues, pursuant to Section 4.1. 

 

	 	(2)	 Beginning in the first year after the FIRST COMMERCIAL SALE of the first LICENSED PRODUCT and in each year
thereafter during the term of this Agreement: Twenty Five Thousand Dollars ($25,000). Each such Annual Fee is payable with the applicable semi-annual royalty report in which the Annual Fee accrues, pursuant to Section 4.2. Should this Agreement
terminate or expire other than on a June 30, the Annual Fee for such portion of a year during the term of the Agreement shall be determined by multiplying the amount set forth above for the given year by a fraction, the numerator of which shall
be the number of days since the prior June 30 during which the Agreement is in effect and the denominator of which shall be three hundred and sixty-five (365). 

(g) LICENSEE shall pay to MICHIGAN the following one-time milestone payments: 

 

	 	(1)	 Upon cumulative NET SALES of all LICENSED PRODUCTS equaling [***] Dollars ($[***]): [***] Dollars ($[***]) due
within [***] days after the financial quarter in which such milestone was achieved. 

  

	 	(2)	 Upon cumulative NET SALES of all LICENSED PRODUCTS equaling [***] Dollars ($[***]): [***] Dollars

  

					
		  		  	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
		  	6	  	

	 	(3)	 ($[***]) due within [***] days after the financial quarter in which such milestone was achieved.

 Milestone payments are non-refundable and
non-creditable against any royalties otherwise due under this Agreement. For clarity, each of the above milestone payments shall be made only once under this Agreement, when such milestone event was first
triggered. 
 3.2         LICENSEE shall be responsible for the payment of all taxes, duties, levies, and other
charges (other than income tax) imposed by any taxing authority with respect to the royalties payable to MICHIGAN under this Agreement. Should LICENSEE be required under any law or regulation of any government entity or authority to withhold or
deduct any portion of the payments on royalties due to MICHIGAN, then such withholding or deduction shall be deducted from the royalties paid to MICHIGAN, and LICENSEE shall promptly furnish MICHIGAN with copies of all official receipts for such
deduction. 
 Each party will obtain, or assist the other party in obtaining, any tax reduction (including avoidance of double taxation), tax refund or tax
exemption available to the parties by treaty or otherwise. 
 3.3         LICENSEE is not obligated to pay multiple
royalties if any LICENSED PRODUCT is covered by more than one (1) VALID CLAIM of the PATENT RIGHTS or the same LICENSED PRODUCT is covered by VALID CLAIMS in two (2) or more countries. 

3.4         Royalty payments due hereunder shall be made to “The Regents of the University of Michigan” in
United States dollars. Payments drawn directly on a U.S. bank may be made by either check to the address in Article 13 or by wire transfer. Any payment drawn on a foreign bank or foreign branch of a U.S. bank shall be made only by wire transfer.
Wire transfers shall be made in accordance with the following or any other written instructions as may be specified by [***]. In computing royalties, LICENSEE shall convert any revenues it receives in foreign currency into its equivalent in United
States dollars at the most recent exchange rate published in the Wall Street Journal on the last business day of the ROYALTY PERIOD during which such payments are received by LICENSEE, or at such other exchange rate as the parties may agree to in
writing. 
 3.5         Royalty payments shall be made on a semi-annual basis with submission of the reports
required by Article 4. All amounts due under this Agreement, including amounts due for the payment of patent expenses, shall, if overdue, be subject to a charge of interest, at a per annum rate of [***]. The payment of such interest shall not
foreclose MICHIGAN from exercising any other rights it may have resulting from any late payment. 

  

					
		  		  	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
		  	7	  	

 ARTICLE 4 — REPORTS 

4.1         Until the FIRST COMMERCIAL SALE of the first LICENSED PRODUCT, LICENSEE shall provide to MICHIGAN a
written annual report on or before July 30 of each year. The annual report shall include: reports of progress on research and development, regulatory approvals, manufacturing, and sublicensing with respect to LICENSED PRODUCTS during the
preceding twelve (12) months, and plans for the coming year. LICENSEE also shall report to MICHIGAN the date of FIRST COMMERCIAL SALE of each LICENSED PRODUCT in each country within thirty (30) days of occurrence. All reports provided by
LICENSEE to MICHIGAN pursuant to this Section 4.1 shall be CONFIDENTIAL INFORMATION of LICENSEE. 
 4.2
        After the FIRST COMMERCIAL SALE of the first LICENSED PRODUCT, LICENSEE shall provide semi-annual royalty reports to MICHIGAN. By each July 30 and January 31 (i.e., within one month after
each ROYALTY PERIOD closes, including the close of the ROYALTY PERIOD immediately following any termination of this Agreement), LICENSEE shall report to MICHIGAN for that ROYALTY PERIOD the NET SALES for such ROYALTY PERIOD. 

(a) NET SALES, excluding the deductions provided therefor, of LICENSED PRODUCTS and LICENSED PROCESSES sold, distributed, used, rented,
leased, or licensed, however characterized, by LICENSEE and all SUBLICENSEES. 
 (b) deductions applicable as provided in the definition for
NET SALES above. 
 (c) royalties due during such ROYALTY PERIOD. 

(d) foreign currency conversion rate and calculations (if applicable). 

(e) any milestone (under Article 3 or Article 5) that has been achieved, and any milestone that was due during the ROYALTY PERIOD but not
achieved, specifying each milestone and whether or not it was achieved. 
 LICENSEE shall include the amount of all payments due, including any payments due
from any sublicense agreement, and the various calculations used to arrive at those amounts, including the quantity, description (nomenclature and type designation as described in Paragraph 4.3 below), country of manufacture, and country of sale or
use of LICENSED PRODUCTS and LICENSED PROCESSES. 
 If no payment is due, LICENSEE shall so report to MICHIGAN that no payment is due. All reports provided
by LICENSEE to MICHIGAN pursuant to this Section 4.2 shall be CONFIDENTIAL INFORMATION of LICENSEE. 
 4.3
        Following the FIRST COMMERCIAL SALE of the first LICENSED PRODUCT, LICENSEE shall promptly establish and consistently employ a system of specific nomenclature and type designations for LICENSED
PRODUCTS to permit identification and segregation of various types where necessary. LICENSEE shall consistently employ, and shall use commercially reasonable efforts to require SUBLICENSEES to consistently employ, the system when rendering invoices
thereon and shall inform MICHIGAN, or its auditors (pursuant to Section 4.4.), when requested, as to the details concerning such nomenclature system, all additions thereto and changes therein. 

  

					
		  		  	
		  	8    	  	

 4.4         LICENSEE shall keep, and shall require SUBLICENSEES to
keep, true and accurate records containing data reasonably required for the computation and verification of payments due under this Agreement. LICENSEE shall, and it shall require all SUBLICENSEES to: (a) open such records for inspection upon
reasonable written notice during business hours, and no more than once per year, by MICHIGAN through an independent certified accountant selected by MICHIGAN and reasonably acceptable to LICENSEE, for the purpose of verifying the amount of payments
due; and (b) retain such records for three (3) years from date of origination. Such independent certified accountant shall enter into an acceptable confidentiality agreement with LICENSEE to treat as confidential all relevant matters of
the inspection. 
 The terms of this Section 4.4 shall survive any termination of this Agreement. MICHIGAN is responsible for all expenses of such
inspection, except that if any inspection reveals an underpayment greater than [***] percent ([***]%) of royalties due MICHIGAN, then LICENSEE shall pay [***] to MICHIGAN within thirty (30) days of written notice thereof. 

4.5         So that MICHIGAN may pay the proper U.S. Patent and Trademark Office fees relating to the PATENT RIGHTS,
if LICENSEE, its AFFILIATE or SUBLICENSEE does not qualify as a “Small Entity” under U.S. patent laws, LICENSEE shall promptly notify MICHIGAN. The parties understand that the changes to LICENSEE’s, its AFFILIATE’s or
SUBLICENSEE’s businesses that might affect entity status include: acquisitions, mergers, hiring of a total of more than five hundred (500) total employees, sublicense agreements, and sublicense options. 

ARTICLE 5 — DILIGENCE 
 5.1
        LICENSEE shall use commercially reasonable efforts to bring at least one (1) LICENSED PRODUCT to market through the exploitation of the PATENT RIGHTS and to market at least one (1) LICENSED
PRODUCT following such FIRST COMMERCIAL SALE. LICENSEE has the responsibility to obtain and retain any governmental approvals to manufacture and/or sell LICENSED PRODUCTS for all relevant activities of LICENSEE hereunder. 

5.2         As part of the diligence required by Section 5.1, LICENSEE agrees to reach the following development
milestone for the LICENSED PRODUCTS by the following date: 
 submit all necessary data and documentation for a Technical Assessment by the
Palmetto GBA MolDx program (or by any applicable Medicare Administrative Contractor program) by March 31, 2015, with such timeline to be extended by any delays caused by any events or factors (including but not limited to changes in applicable
regulations) that are out of the reasonable control of LICENSEE. 

  

					
		  		  	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
		  	9	  	

 ARTICLE 6 — SUBLICENSING 

6.1         LICENSEE shall notify MICHIGAN in writing of every sublicense agreement and each material amendment
thereto within thirty (30) days after their execution, and indicate the name of the SUBLICENSEE, the territory covered by the sublicense, the scope of the sublicense, and the nature, timing and amounts of all fees and royalties to be paid
thereunder. LICENSEE will provide to MICHIGAN a redacted copy of the sublicense agreement (or material amendment, as applicable) in a form permitted by the SUBLICENSEE. 

6.2         To the extent LICENSEE receives from SUBLICENSEES any consideration other than cash for such sublicense
agreements, fair market cash value (at the time of the transaction) for such consideration will be agreed upon by the parties. 
 6.3
        Each sublicense granted by LICENSEE under this Agreement shall provide for its termination upon termination of this Agreement. Each sublicense shall terminate upon termination of this Agreement unless
LICENSEE has previously assigned its rights under the sublicense to MICHIGAN, provided that, notwithstanding the foregoing, for a period of [***] days after termination of this Agreement, MICHIGAN agrees to negotiate in good faith with each
SUBLICENSEE that (a) is not under common control or ownership with LICENSEE, and (b) is not in material breach of its sublicense with LICENSEE at the time of the termination of this Agreement, to provide such SUBLICENSEE a license under
the PATENT RIGHTS on similar financial terms contained in this Agreement with respect to the rights granted by LICENSEE to such SUBLICENSEE. 
 6.4
        LICENSEE shall require that all sublicenses: 
 (a) be consistent with the terms and
conditions of this Agreement; 
 (b) contain the SUBLICENSEE’S acknowledgment of the disclaimer of warranty and limitation on
MICHIGAN’s liability, as provided by Article 9 below; and 
 (c) contain provisions under which the SUBLICENSEE accepts duties at least
equivalent to those accepted by the LICENSEE in the following Paragraphs: 4.4 (duty to keep records); 4.5 (duty regarding Patent Office fees); 9.4 (duty to avoid improper representations or responsibilities); 10.1 and 10.2 (duty to defend, hold
harmless, and indemnify MICHIGAN and HHMI); 10.3 (duty to maintain insurance); 14.5 (duty to properly mark LICENSED PRODUCTS with patent notices); 14.7 (duty to restrict the use of MICHIGAN and HHMI’s name); 14.8 (duty to control exports). 

ARTICLE 7 — PATENT APPLICATIONS AND MAINTENANCE 

7.1         Subject to Section 7.3, MICHIGAN has the first right and responsibility to control all aspects of
filing, prosecuting, and maintaining all of the patents and patent applications that are contained within the PATENT RIGHTS, interferences, and disputes (including litigation) regarding inventorship, in each case in cooperation with LICENSEE in
accordance with Section 7.2, and using counsel reasonably acceptable to LICENSEE. LICENSEE shall fully cooperate in such activities. 

  

					
		  		  	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
		  	10	  	

 7.2         MICHIGAN shall promptly (and reasonably prior to any
deadline or action with the U.S. Patent and Trademark Office or any foreign patent office) notify and provide copies to LICENSEE of all information and documents received by MICHIGAN relating to the filing, prosecution and maintenance of the patents
and patent applications that are contained within the PATENT RIGHTS. LICENSEE shall have the right to review, comment, and advise upon all such information, including providing to MICHIGAN and/or MICHIGAN’s counsel the initial draft of any
response or document related thereto, and MICHIGAN agrees to implement in good faith all reasonable and timely requests made by LICENSEE. Each party agrees to hold such information confidential and to use the information provided by MICHIGAN or
LICENSEE only for the purpose of advancing the PATENT RIGHTS. 
 7.3         MICHIGAN shall not abandon any patent
or patent application within the PATENT RIGHTS without reasonable prior notice to LICENSEE (in any event at least sixty (60) days prior to any deadline or action with the U.S. Patent and Trademark Office or applicable foreign patent office).
Upon receiving such notice LICENSEE shall have the right, but not obligation, to assume all aspects of filing, prosecuting, and maintaining of any such patent or patent application. 

7.4         LICENSEE shall reimburse MICHIGAN for all reasonable fees and costs relating to the activities described
in this Article on a pro-rated basis based on the number of MICHIGAN licensees or optionees of the PATENT RIGHTS or any portion thereof provided, however, that starting with calendar year 2013 such fees
and costs shall be consistent with an annual budget to be agreed upon by the parties before the start of each calendar year. Reimbursement by LICENSEE shall be made within thirty (30) days of receipt of MICHIGAN’s invoice and shall be
subject to the interest specified in Section 3.5 above. 
 ARTICLE 8 — ENFORCEMENT 

8.1         Each party shall promptly advise the other in writing of any known acts of potential infringement of the
PATENT RIGHTS by third party. LICENSEE has the first right to police the PATENT RIGHTS against infringement by third parties within the TERRITORY and the FIELD OF USE, but LICENSEE shall notify MICHIGAN twenty (20) days before filing any suit;
notwithstanding, LICENSEE may so notify MICHIGAN one (1) day before filing any such suit if circumstances exist to make such twenty (20)-day notice impossible and LICENSEE notifies MICHIGAN as soon as
reasonably possible. LICENSEE shall not file any suit without a diligent investigation of the merits of such suit by its counsel, including with respect to PATENT RIGHTS. This right to police includes defending any action for declaratory judgment of
noninfringement or invalidity; and prosecuting, defending or settling all infringement and declaratory judgment actions at its expense and through counsel of its selection, except that LICENSEE shall make any such settlement only with the advice and
consent of MICHIGAN. If LICENSEE has a reasonable basis for policing the patents and has provided said twenty (20) days notice (or such shorter period as permitted herein), MICHIGAN shall provide reasonable assistance to LICENSEE with respect
to such actions, including at the request of LICENSEE, joining such actions as a party if MICHIGAN is a necessary party to the lawsuit, but only if LICENSEE reimburses MICHIGAN for
out-of-pocket expenses incurred by MICHIGAN in connection with any such assistance rendered at LICENSEE’S request or reasonably required by

  

					
		  		  	
		  	11	  	

 
MICHIGAN. MICHIGAN retains the right to participate, with counsel of its own choosing and at its own expense, in any action under this Section 8.1. 

If a claim or counterclaim is made by any third party that any of the PATENT RIGHTS is invalid or unenforceable, then MICHIGAN, at its sole option, shall have
the right to intervene and assume control over the defense of such claim or counterclaim, and LICENSEE shall provide reasonable cooperation in the defense of such claim or counterclaim; provided, however, that MICHIGAN shall not make any
settlement with respect to such claim or counterclaim without the advice and consent of LICENSEE, such consent not to be unreasonably withheld, conditioned or delayed, If a third party asserts jurisdiction for any such action solely as the result of
acts of MICHIGAN and MICHIGAN exercises it right to control, then MICHIGAN shall be responsible for the reasonable costs and fees of defending such action, but otherwise the remainder of this Section 8.1 shall control. 

8.2         If LICENSEE recovers under this Article 8 damages in patent litigation or settlement thereof, the award
shall be applied first to satisfy LICENSEE’S and MICHIGAN’s reasonable expenses and legal fees for the litigation. The remaining balance shall be divided between the parties as follows: [***] percent ([***]%) to LICENSEE and [***] percent
([***]%) to MICHIGAN; provided, however, that to the extent such patent litigation or settlement thereof relates to this Agreement and other third party licenses to LICENSEE, such [***] percent ([***]%) allocation to MICHIGAN shall be [***]
between MICHIGAN and any such third party licensor(s). This provision shall control the division of revenues where a license is granted as part of a settlement of such lawsuit. 

8.3         If LICENSEE fails to take action to abate any alleged infringement of patents within the PATENT RIGHTS
within ninety (90) days of a written request by MICHIGAN to do so (or within a shorter period if required to preserve the legal rights of MICHIGAN under any applicable laws) then MICHIGAN has the right to take such action (including prosecution
of a suit) at its expense and LICENSEE shall use reasonable efforts to cooperate in such action, at MICHIGAN’S request and expense. During such action LICENSEE shall not have the right to grant sublicenses without MICHIGAN’s permission,
such permission not to be unreasonably withheld, and MICHIGAN has full authority to settle on such terms as MICHIGAN determines, provided that such settlement terms do not adversely affect any of LICENSEE’s rights hereunder. If MICHIGAN
recovers damages in patent litigation or settlement thereof, the award shall be applied first to satisfy LICENSEE’S and MICHIGAN’s reasonable expenses and legal fees for the litigation. The remaining balance shall be [***] LICENSEE and
MICHIGAN. This provision shall control the division of revenues where a license is granted as part of a settlement of such litigation. 

ARTICLE 9 — NO WARRANTIES; LIMITATION ON MICHIGAN’S LIABILITY 

9.1         MICHIGAN, including its Regents, fellows, officers, employees and agents, makes no representations or
warranties that the PATENT RIGHTS are or will be held valid or enforceable, or that the manufacture, importation, use, offer for sale, sale or other distribution of any LICENSED PRODUCTS will not infringe upon any third party’s patent or other
intellectual property rights. 

  

					
		  		  	[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED
		  	12	  	

 9.2         MICHIGAN, INCLUDING ITS REGENTS, FELLOWS,
OFFICERS, EMPLOYEES AND AGENTS, MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO
RESPONSIBILITIES WHATEVER WITH RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION BY LICENSEE OR SUBLICENSEES OF LICENSED PRODUCTS. 

9.3         LICENSEE AND SUBLICENSEES ASSUME THE ENTIRE RISK AS TO PERFORMANCE OF LICENSED
PRODUCTS. In no event shall MICHIGAN, including its Regents, fellows, officers, employees and agents, be responsible or liable for any direct, indirect, special, incidental, or consequential damages or lost profits or other economic loss or
damage with respect to LICENSED PRODUCTS, to LICENSEE, SUBLICENSEES or any other individual or entity regardless of legal or equitable theory. The above limitations on liability apply even though MICHIGAN, its Regents, fellows, officers, employees
or agents may have been advised of the possibility of such damage. 
 9.4         LICENSEE shall not, and shall
require that its SUBLICENSEES do not, make any statements, representations or warranties whatsoever to any person or entity, or accept any liabilities or responsibilities whatsoever from any person or entity, that are inconsistent with any
disclaimer or limitation included in this Article 9. 
 ARTICLE 10 — INDEMNITY; INSURANCE 

10.1         LICENSEE shall defend, indemnify and hold harmless and shall require SUBLICENSEES to defend, indemnify
and hold harmless MICHIGAN, including its Regents, fellows, officers, employees, students, and agents (collectively, “MICHIGAN Indemnitees”), for and against any and all damages, losses, and expenses of any nature (including
attorneys’ fees and other litigation expenses), including but not limited to, death, personal injury, illness, property damage, economic loss or products liability (collectively, “Losses”), based on third party claims or demands
arising from or in connection with any of the following: (1) Any manufacture, use, sale or other disposition by LICENSEE, its AFFILIATES SUBLICENSEES or LICENSEE’S transferees of LICENSED PRODUCTS or LICENSED PROCESSES, including any
product liability actions; and (2) The use or practice by LICENSEE, its AFFILIATES or SUBLICENSEES of the PATENT RIGHTS; except to the extent such Losses arise from the negligence or willful misconduct of a MICHIGAN Indemnitee. 

10.2         HHMI and its trustees, officers, employees, and agents (collectively, “HHMI Indemnitees”), will
be indemnified, defended by counsel reasonably acceptable to HHMI, and held harmless by the LICENSEE and SUBLICENSEES from and against any third party claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature
(including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively, “Claims”), based upon, arising out of, or otherwise relating to this Agreement, including without limitation any cause
of action relating to product liability. The previous sentence will not apply to the extent any Claim is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI
Indemnitee. 

  
 13 

 10.3         If MICHIGAN (the “Indemnified Party”) is
seeking indemnification under Section 10.1, the Indemnified Party shall inform LICENSEE or SUBLICENSEE (as applicable, the “Indemnifying Party”) of the claim giving rise to the obligation to indemnify as soon as reasonably practicable
after receiving notice of the claim. The Indemnifying Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party
and its insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party shall have the right to participate, at its own option and expense, through counsel of its own selection,
in the defense of any claim that has been assumed by the Indemnifying Party. The Indemnifying Party shall not settle any such legal action with an admission of liability of the Indemnified Party without the Indemnified Party’s written approval,
which approval shall not be unreasonably withheld or delayed. 
 In the case of any HHMI Indemnitee, notice shall be given reasonably promptly following
actual receipt of written notice thereof by an officer or attorney of HHMI. Notwithstanding the foregoing, the delay or failure of any HHMI Indemnitee to give reasonably prompt notice to the Indemnifying Party of any such claim shall not affect the
rights of such HHMI Indemnitee unless, and then only to the extent that, such delay or failure is prejudicial to or otherwise adversely affects the Indemnifying Party. The Indemnifying Party shall have the right to assume the defense of any such
claim for which it is obligated to indemnify any HHMI Indemnitee. An HHMI Indemnitee shall cooperate with the Indemnifying Party and its insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense.
An HHMI Indemnitee shall have the right to participate, at its own option and expense, through counsel of its own selection, in the defense of any claim that has been assumed by the Indemnifying Party. 

The Indemnifying Party agrees not to settle any Claim against an HHMI Indemnitee without HHMI’s written consent, where (a) such settlement would
include any admission of liability on the part of any HHMI Indemnitee, (b) such settlement would impose any restriction on any HHMI Indemnitee’s conduct of any of its activities, or (c) such settlement would not include an
unconditional release of all HHMI Indemnitees from all liability for claims that are the subject matter of the settled Claim. 
 10.4
        Prior to any distribution or commercial use of any LICENSED PRODUCT by LICENSEE, LICENSEE shall purchase and maintain in effect commercial general liability insurance, including product liability
insurance and errors and omissions insurance which shall protect LICENSEE, MICHIGAN and HHMI Indemnitees with respect the events covered by Sections 10.1 and 10.2. Prior to any distribution or use of any LICENSED PRODUCT by a SUBLICENSEE, LICENSEE
shall require that the SUBLICENSEE purchase and maintain in effect commercial general liability insurance, including product liability insurance and errors and omissions insurance which shall protect LICENSEE, SUBLICENSEE, MICHIGAN and HHMI
Indemnitees with respect to the events covered by Section 10.1. Each such insurance policy must provide industry-standard coverage for all claims with respect to any LICENSED PRODUCTS manufactured, used, sold, licensed or otherwise distributed
by LICENSEE -- or, in the case of a SUBLICENSEE’s policy, by said SUBLICENSEE -- and must specify HHMI Indemnitees and MICHIGAN Indemnitees as additional insured where applicable. LICENSEE 

  
 14 

 
shall furnish certificate(s) of such insurance to MICHIGAN prior to FIRST COMMERCIAL SALE. 
 10.5
        IN NO EVENT SHALL EITHER PARTY HEREUNDER BE LIABLE TO THE OTHER FOR ANY SPECIAL, INDIRECT, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER RESULTING FROM ANY BREACH OR DEFAULT OF THIS AGREEMENT. 

ARTICLE 11 — TERM AND TERMINATION 

11.1         If LICENSEE ceases to carry on its business, this Agreement shall terminate upon written notice by
MICHIGAN attempted to be delivered to the then-current address for notices provided in Article 13. 
 11.2
        Upon any material breach or default of this Agreement by a party (other than as specifically provided herein, the terms of which shall take precedence over the handling of any other material breach or
default under this Section 11.2), the other party has the right to terminate this Agreement effective on sixty (60) days’ written notice to provide an opportunity to cure the breach or default. Such termination shall become
automatically effective upon expiration of the sixty (60)-day period unless the material breach or default is cured before such period expires; provided, however, that the party receiving notice of
breach has the right to dispute in good faith, the termination under this Section 11.2 and this Agreement may not be terminated unless and until: (a) the dispute has been resolved in favor of the party originally delivering the notice of
breach, and (b) the breach is not cured within fifteen (15) days thereafter; provided, further, that if the dispute relates to LICENSEE’s payment obligations hereunder, LICENSEE shall first pay to MICHIGAN such amounts before
disputing the termination under this Section 11.2. In no event shall such termination abeyance last longer than 180 days from the date of notice of good faith dispute. 

11.3         LICENSEE has the right to terminate this Agreement at any time on ninety (90) days’ written
notice to MICHIGAN. 
 11.4 Upon termination of this Agreement, and except as provided herein to the contrary, all rights and obligations of the parties
hereunder shall cease, except any previously accrued rights and obligations, and the following shall apply: 
 (a) LICENSEE has the
obligation to pay royalties and other sums, or to transfer equity or other consideration, accruing hereunder up to the day of such expiration or termination, whether or not this Agreement provides for a number of days before which actual payment is
due and such date is after the day of expiration or termination and whether or not a required funding event or other stock transfer trigger has yet been met; 

(b) LICENSEE will submit a final report of the type described in Section 4.1 or 4.2, as applicable; 

  
 15 

 (c) MICHIGAN shall have the right to inspect books and records as described in Article 4,
but only for so long as LICENSEE’s obligations to keep such records for the required time; 
 (d) LICENSEE will cease its manufacture,
use and sale of the LICENSED PRODUCTS and LICENSED PROCESSES; 
 (e) Any cause of action or claim of LICENSEE or MICHIGAN accrued or to
accrue because of any breach or default by the other party hereunder shall survive; 
 (f) The provisions of Sections 2.3, 6.3 and 11.4 and
Articles 1, 9, 10, and 14 shall survive; and 
 (g) All other terms, provisions, representations, rights and obligations contained in this
Agreement that by their sense and context are intended to survive until performance thereof by either or both parties shall survive. 
 11.5
        If LICENSEE asserts the invalidity or unenforceability of any VALID CLAIM included in the PATENT RIGHTS, including by way of litigation or administrative proceedings, either directly or indirectly
through any other party, then MICHIGAN shall have the right to immediately terminate this Agreement upon written notice to LICENSEE. In the event such assertion of invalidity or unenforceability is made by a SUBLICENSEE, LICENSEE will terminate any
and all rights granted to such SUBLICENSEE. In the event the SUBLICENSEE does not withdraw such legal action, LICENSEE will fully cooperate with MICHIGAN in defending the PATENT RIGHTS at MICHIGAN’s request and expense. 

ARTICLE 12 — REGISTRATION AND RECORDATION 

12.1         If the terms of this Agreement, or any assignment or license under this Agreement are or become such as
to (by applicable law) require that the Agreement or license or any part thereof be registered with or reported to a national or supranational agency, LICENSEE will, at its expense, undertake such registration or report. Prompt notice and
appropriate verification of the act of registration or report or any agency ruling resulting from it will be supplied by LICENSEE to MICHIGAN upon request. 

12.2         LICENSEE shall also carry out, at its expense, any formal recordation of this Agreement or any license
herein granted that the law of any country requires as a prerequisite to enforceability of the Agreement or license in the courts of any such country or for other reasons, and shall promptly furnish to MICHIGAN appropriately verified proof of
recordation. 
 ARTICLE 13 — NOTICES 

13.1         Any notice, request, or report required or permitted to be given or made under this Agreement by either
party is effective: on the date delivered in person; one (1) day after mailing if sent by an internationally recognized overnight carrier with charges prepaid; three (3) days after mailing if sent by certified or registered mail postage
prepaid and return receipt requested; 

  
 16 

 
or on the date transmitted by facsimile, if confirmation is received, in each case to the address set forth below or such other address as such party specifies by written notice given in
conformity herewith. Any notice, request, or report not so given is not effective until actually received by the other party. 
  

			
	 To MICHIGAN:
  

Office of Technology Transfer
 University of Michigan

1600 Huron Parkway, 2nd Floor
 Ann Arbor, MI 48109-2590

Facsimile: 734-615-8433

Attn: File No. 4774 and 5424
	  	 To LICENSEE:
  

GenomeDx Biosciences, Inc.
 311 Water Street, 4th Floor
 Vancouver, B.C., Canada, V6B 1B8

 
 Facsimile: (866) 505-5161

Attn: Chief Financial Officer

 ARTICLE 14 — MISCELLANEOUS PROVISIONS 

14.1         This Agreement shall be construed, governed, interpreted and applied according to United States and State
of New York law, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent was granted. 

14.2         Should LICENSEE bring any claim, demand or other action against MICHIGAN, its Regents, fellows, officers,
employees or agents, arising out of this Agreement or the relationship between the parties, LICENSEE agrees to bring said action only in the Michigan Court of Claims. 

14.3         In the event of disputes between the parties arising out of or in connection with this Agreement, the
parties agree to attempt to resolve such disputes by good faith discussions by and among the senior individuals with responsibility for patent and licensing activities at the disputing parties’ institutions, with advice of patent counsel, if
necessary. Where disputes cannot be resolved by mutual agreement, the disputing parties agree to submit to non-binding mediation using procedures to be negotiated in good faith, with the intent of resolving
disputes short of litigation, except that with respect to matters of patent law, the parties shall be entitled to pursue any legal remedies available. 

14.4         MICHIGAN and LICENSEE agree that this Agreement, including any Exhibits, sets forth their entire
understanding concerning the subject matter of this Agreement. The parties may amend this Agreement from time to time, such as to add new or to modify rights, but no modification will be effective unless both MICHIGAN and LICENSEE agree to it in
writing. 
 14.5         If a court of competent jurisdiction finds any term of this Agreement invalid, illegal or
unenforceable, that term will be curtailed, limited or deleted, but only to the extent necessary to remove the invalidity, illegality or unenforceability, and without in any way affecting or impairing the remaining terms. 

14.6         LICENSEE agrees to use reasonable efforts to mark the LICENSED PRODUCTS sold in the United States with
all applicable United States issued patent numbers. All LICENSED 

  
 17 

 
PRODUCTS shipped to or sold in other countries shall be marked to comply with the applicable patent laws and practices of the countries of manufacture, use and sale. 

14.7        No waiver by either party of any breach of this Agreement, no matter how long continuing or how often
repeated, is a waiver of any subsequent breach thereof, nor is any delay or omission on the part of either party to exercise or insist on any right, power, or privilege hereunder a waiver of such right, power or privilege. In no event shall any
waiver be deemed valid unless it is in writing and signed by an authorized representative of each party. 

14.8        LICENSEE agrees to refrain from using and to require SUBLICENSEES to refrain from using the name of
MICHIGAN or HHMI in publicity or advertising without the prior written approval of MICHIGAN and/or HHMI, as the case may be, except as may be required by law. Reports in scientific literature and presentations of joint research and development work
are not publicity. Notwithstanding this provision, without prior written approval of MICHIGAN, LICENSEE, its AFFILIATES and SUBLICENSEES may state publicly (including on their respective websites) that LICENSED PRODUCTS were developed by LICENSEE
based upon an invention(s) developed at the University of Michigan and/or that the PATENT RIGHTS were licensed from the University of Michigan. 

14.9        LICENSEE agrees to comply with all applicable laws and regulations. In particular, LICENSEE understands
and acknowledges that the transfer of certain commodities and technical data is subject to United States laws and regulations controlling the export of such commodities and technical data, including all Export Administration Regulations of the
United States Department of Commerce. These laws and regulations prohibit or require a license for the export of certain types of technical data to certain specified countries. LICENSEE agrees to comply with all United States laws and regulations
controlling the export of commodities and technical data, to be solely responsible for any violation of such laws and regulations by LICENSEE, its AFFILIATES or SUBLICENSEES, and to defend, indemnify and hold harmless MICHIGAN and its Regents,
fellows, officers, employees and agents if any legal action of any nature results from the violation of such laws and regulations by LICENSEE, its AFFLIATES or SUBLICENSEES. 

14.10        The relationship between the parties is that of independent contractor and contractee. Neither party is
an agent of the other in connection with the exercise of any rights hereunder, and neither has any right or authority to assume or create any obligation or responsibility on behalf of the other. 

14.11        LICENSEE may not assign this Agreement without the prior written consent of MICHIGAN, such consent not to
be unreasonably withheld. LICENSEE shall not pledge any of the license rights granted in this Agreement as security for any creditor without the consent of MICHIGAN. Any attempted pledge of any of the rights under this Agreement or attempted
assignment of this Agreement in contravention of the foregoing will be void from the beginning. No assignment by LICENSEE (to which MICHIGAN consented) will be effective until the intended assignee agrees in writing to accept all of the terms and
conditions of this Agreement, and such writing is provided to MICHIGAN. Notwithstanding any of the foregoing, LICENSEE may, without MICHIGAN’s consent, assign its rights and obligations under this Agreement to an AFFILIATE or a purchaser of all
or substantially all of LICENSEE’s stocks or assets relating to 

  
 18 

 
the subject matter of this Agreement, so long as such assignee provides a statement in writing to MICHIGAN that it agrees to accept all the terms and conditions of this Agreement in the place of
LICENSEE. 
 14.12         If during the term of this Agreement, LICENSEE makes or attempts to make an assignment
for the benefit of creditors, or if proceedings in voluntary or involuntary bankruptcy or insolvency are instituted on behalf of or against LICENSEE and not dismissed within ninety (90) days, or if a receiver or trustee is appointed for the
property of LICENSEE, this Agreement shall automatically terminate. LICENSEE shall notify MICHIGAN of any such event mentioned in this Section 14.12 as soon as reasonably practicable, and in any event within five (5) business days after
any such event. 
 14.13         HHMI is not a party to this Agreement and has no liability to any licensee,
sublicensee, or user of anything covered by this Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of its provisions are for the benefit of HHMT and are enforceable by HHMI in its own name. 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly authorized officers or representatives as of the
Effective Date. 
  

									
	 FOR
 GENOMEDX BIOSCIENCES,
INC.
	 		 	 FOR THE REGENTS OF THE
 UNIVERSITY
OF MICHIGAN

					
	By:	 	 /s/ David Matthews
	 		 	By:	 	 /s/ Kenneth Nisbet

	(authorized representative)	 		 		 	Kenneth J. Nisbet
		 		 		 		 	Executive Director, UM Technology Transfer
	Typed Name: David
Matthews                                    	 		 		 	
					
	Title:	 	
CFO                    
                                        
	 		 		 	

  
 19EX-10.17

 Exhibit 10.17 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 PATENT AND KNOW-HOW LICENSE
AGREEMENT 
 This Patent and Know-How License Agreement (“Agreement”)
is entered into as of February 1, 2013 (“Effective Date”) by and between Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota
55905-0001 (“Mayo”), and GenomeDx Biosciences, Inc., a corporation having its principal place of business at 311 Water Street, 4th Floor, Vancouver, B.C., Canada, V6B 1B8
(“Company”). 
 WHEREAS, Mayo desires to make its intellectual property rights available for the development and
commercialization of products, methods and processes for public use and benefit; 
 WHEREAS, Company discovers, develops and
commercializes genomic-based laboratory tests for use in personalized medicine; and 
 WHEREAS, Mayo is willing to grant and
Company is willing to accept an exclusive license under Mayo’s patents, patent applications and know-how for the purpose of developing and commercializing products incorporating biomarkers
for cancer diagnostic assays. 
 NOW THEREFORE, in consideration of the foregoing and the terms and conditions set forth
below, the parties hereby agree as follows: 
 Article 1.00 – Definitions 

For purposes of this Agreement, the terms defined in this Article will have the meaning specified and will be applicable both to the singular
and plural forms: 
 1.01    For Mayo, “Affiliate”: any corporation or other entity within the same
“controlled group of corporations” as Mayo or its parent Mayo Clinic. For purposes of this definition, the term “controlled group of corporations” will have the same definition as Section 1563 of the Internal Revenue Code as
of November 10, 1998, but will include corporations or other entities which if not a stock corporation, more than 50% of the board of directors or other governing body of such corporation or other entity is controlled by a corporation within
the controlled group of corporations of Mayo or Mayo Clinic. Mayo’s Affiliates include, but are not limited to: Mayo Clinic; Mayo Collaborative Services, Inc.; Rochester Methodist Hospital; Saint Marys Hospital; Mayo Clinic Rochester; Mayo
Clinic Florida; Mayo Clinic Arizona; and its Mayo Health System entities. 
 For Company, “Affiliate”: any corporation or other
entity that controls, is controlled by, or is under common control with, Company. For purposes of this definition, “control” means direct or indirect ownership of: (a) at least 50% or the maximum percentage, if less than 50%, as
allowed by applicable law, of the outstanding voting securities or equity interest of such entity; or (b) at least 50% of the decision-making authority of such entity. 

1.02    “Confidential Information” of a party: any and all proprietary information of such party that is
disclosed or transferred to the other party under this Agreement, whether in oral, written, graphic or electronic form. Confidential Information does not include any information or material that receiving 

 party can demonstrate by competent evidence is: (a) already known to the receiving
party at the time of disclosure (other than from the disclosing party or under an obligation of confidentiality); (b) publicly known or becomes publicly known other than through acts or omissions of the receiving party; (c) disclosed to the
receiving party by a third party who was not and is not under any obligation of confidentiality, and who did not obtain such information directly or indirectly from the disclosing party; or (d) independently developed by employees of the
receiving party without knowledge of or access to the other party’s Confidential Information. 

1.03    “Field”: all fields of use. 

1.04    “IP Rights”: (a) [***]; (b) any and all patent applications arising from the collaboration
as defined in the 2009 Agreement; (c) all applications and patents claiming priority to applications included in (a) or (b), including any continuation,
continuation-in-part (but only for subject matter supported pursuant to 35 U.S.C. §112 by the foregoing), divisionals, substitution, reissue, reexamination;
(d) any patents issuing from any of the foregoing set forth in (a) through (c); (e) any foreign counterpart of any of the foregoing set forth in (a) through (d); and (f) any other intellectual property rights including copyrights
and trade secrets to arise during the collaboration of the parties under the 2009 Agreement. The patents and patent applications within IP Rights existing as of the Effective Date are set forth in Exhibit A. 

1.05    “Know-How”: (a) information, materials (as agreed upon by
the parties), technical data, clinical data, database records, annotations, results, algorithms, protocols, unpatented inventions, trade secrets, know-how and supportive information (i) developed by
Dr. Robert Jenkins MD, PhD (whether or not in collaboration with others), which is owned and controlled by Mayo as of the Effective Date (including any and all of the foregoing owned or controlled by Mayo under the 2009 Agreement and any
improvements thereof made by either party thereto prior to the Effective Date) or (ii) provided by Mayo to Company prior to and as of the Effective Date, in each case to the extent it is necessary or reasonably useful for the discovery or
validation of biomarkers, or the research, development or manufacture of a Licensed Product, and (b) de-identified clinical annotations and patient follow-up
results and records that are generated for a period of [***] years after the Effective Date pertaining to specimens processed and/or analyzed prior to the Effective Date. Know-How existing as of the Effective
Date include, but are not limited to, those listed on Exhibit B. 

1.06    “Know-How Biomarker”: any biomarker that is not claimed
by a Valid Claim of IP Rights but that is discovered by Company using Know-How, or validated by Company solely using Know-How, in each case that was unpublished at the
time of its use by Company for such discovery or validation. 
 1.07    “Licensed Product”: any
product, process or service that: (a) in the making, using, importing, exporting or selling of such product, process or service would, absent the licenses granted to Company under this Agreement, infringe a Valid Claim of the IP Rights; or
(b) that is discovered or validated by Company using Know-How. 

1.08    “Net Sales”: the amount received by Company, its Affiliates or any Sublicensee for the transfer
of a Licensed Product to a third party, less documented: (a) duties, sales, excise or use taxes or other government charge; (b) credits for defective or returned Licensed Products actually given; (c) regular and 

  
 2 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 customary trade rebates, price reductions and discount allowances given; and
(d) transportation and handling charges or allowances. Net Sales on Licensed Products transferred as part of a non-cash exchange but for value shall be calculated at the then-current customary sales price
invoiced to third parties or fair market value if there are no current invoices to third parties. 
 Net Sales shall not include amounts
related to: (i) the transfer of Licensed Product at cost or less as samples (for marketing, promotion or otherwise) or as donations or for compassionate use, (ii) transfer of Licensed Product at cost or less for use in clinical trials, and
(iii) the sale or other transfer of Licensed Product at cost or less to or between the Company and any of its Affiliates. In the event that Company transfers Licensed Products to an Affiliate, and the Affiliate retransfers the Licensed Products
to third-party customers, then Net Revenue shall be the price charged by the Affiliate to third-party customers, less documented allowable deductions (as described in this Section 1.07). 

For clarity, Licensed Products sold or transferred to Mayo or Mayo’s Affiliates are not considered transfers for purposes of calculating
Earned Royalties and sales milestones under Article 3. 
 Net Sales shall be determined from the books and records of the Company, its
Affiliates and/or Sublicensees maintained in accordance with U.S. generally accepted accounting principles consistently applied. Net Sales for a particular Licensed Product will be calculated by multiplying the total revenue received for such
Licensed Product with a factor (“Multi-Gene Product Factor”) that reflects the relative contribution of the Mayo licensed technology in such Licensed Product, based on the percentage of biomarkers configured in such Licensed Product that
are claimed by a Valid Claim of IP Rights and calculated as set forth below; provided, however, such Multi-Gene Product Factor reflecting the relative contribution of the Mayo licensed technology shall not be below [***] percent
([***]%). 
 The Multi-Gene Product Factor shall be A/B, where A is equal to: (a) the number of Patent Biomarkers; plus (b) the
number of Know-How Biomarkers multipled by [***] percent ([***]%), and B is equal to the sum of the total number of biomarkers included in such Licensed Product, provided that, subsection (b) shall only
be included in such calculation for a particular Know-How Biomarker for the first seven (7) years after the first commercial sale of the applicable Licensed Product containing such Know-How Biomarker. 
 1.09    “Patent Biomarkers”: any biomarker
that is claimed by a Valid Claim of IP Rights. 
 1.10    “Sublicensee”: any third party, excluding
Mayo and its Affiliates, to whom Company has conveyed rights or the forbearance of suit under the license grant to Company in Section 2.01, with respect to the IP Rights and/or Know-How. 

1.11    “Sublicense Income”: consideration received by Company from each Sublicensee directly
attributable to a sublicense of the IP Rights and/or Know-How. Sublicense Income shall exclude any royalty payments received by Company from any Sublicensee, but instead the Company shall pay Mayo royalties on
Net Sales by such Sublicensee as if such sales were made by Company or its Affiliate. Sublicense Income shall also exclude all fees and payments received by Company as a reimbursement of actual cost incurred by Company, including for Company’s
research, development, manufacturing, marketing and/or patent prosecution. Sublicense Income may include any payment received by Company in exchange for Company’s equity but only to the extent such payment amount exceeds the fair market 

  
 3 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 value of such equity at the time of the transaction. 

1.12    “Royalty Term”: on a Licensed
Product-by-Licensed Product and country-by-country basis subject to Article 10 for a
particular Licensed Product in a particular country, begins on the first commercial sale of such Licensed Product in such country and ends upon: (a) for any Licensed Product that contains at least one (1) Patent Biomarker, the date of
expiration of the last Valid Claim in the IP Rights claiming the composition of matter or method of making or using such Patent Biomarker in such country, or, as the case may be (b) for any Licensed Product that does not contain any Patent
Biomarker but contains at least one (1) Know-How Biomarker, seven (7) years after the first commercial sale of such Licensed Product in such country. 

1.13    “Term”: begins on the Effective Date and, unless terminated earlier under Article 10 of this
Agreement, ends on the expiration of the last to expire Royalty Term. 
 1.14    “Territory”:
all of the countries in the world, and their territories and possessions. 
 1.15    “Valid Claim”:
a claim contained in (a) an issued and unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time
allowed for appeal, and which has not been admitted to be invalid or unenforceable through abandonment, disclaimer or otherwise, or (b) a patent application that has not been irretrievably cancelled, withdrawn or abandoned; provided,
however, a Valid Claim shall exclude any claim in (a) or (b) that has been lost as a result of an interference proceeding. 

1.16    “2009 Agreement”: the agreement between Company and Mayo effective as of November 10, 2009,
in which the parties collaborated on a project to discover and identify biomarkers to guide the treatment and management of prostate cancer patients. 

Article 2.00 – Grant of Rights 

2.01    LICENSE GRANT. Subject to the terms and conditions of this Agreement, Mayo hereby grants to Company:
(a) an exclusive license with all rights to sublicense through multiple tiers subject to Mayo’s approval, which approval shall not be unreasonably withheld, delayed or conditioned, within the Field and Territory under the IP Rights to
make, have made, use, offer for sale, sell, and import Licensed Products and to perform services using Licensed Products; and (b) a nonexclusive license with all rights to sublicense through multiple tiers, subject to Mayo’s approval,
which approval shall not be unreasonably withheld, delayed or conditioned, within the Field and Territory to use the Know-How to (i) develop, make, have made, use, offer for sale, sell, and import
Licensed Products and to perform services using Licensed Products, and (ii) discover or validate biomarkers or otherwise perform research as part of Company’s continued research program during and after the 2009 Agreement (subject to any
necessary Mayo IRB approval of any new research as may be required by Federal or State Law). 

2.02    OPTION. Subject to any third party rights at the time and to the extent Mayo owns or controls after
the Effective Date any patent applications and/or patents that would be infringed by the practice of the license granted to Company under Section 2.01, Mayo hereby grants to Company an option to obtain a license (“Option”) to such
patents and patent applications (as well as related know-how) from Mayo on 

  
 4 

 commercially reasonable terms to be negotiated in good faith by the parties. Upon the
receipt of a written notice (a) from Company to Mayo that identifies the above mentioned patents or patent applications (and any related know-how), or (b) from Company to Mayo electing to exercise
the Option, following Company’s receipt of a written notice from Mayo identifying the above mentioned patents or patent applications (and any related know-how) that have come to Mayo’s attention (in
each case of (a) and (b), such written notice from Company shall constitute exercise of the Option), the parties shall have [***] thereafter to negotiate in good faith and conclude a license agreement for such patents or patent applications
(and any related know-how). If the parties fail to reach an agreement on the terms of such license during such [***] period following the exercise of the Option, Mayo shall have no further obligation to the
Company regarding such patents or patent applications (and any related know-how). To the knowledge of Mayo Clinic Ventures, which is a business unit of Mayo, there are no other patents or patent applications
(or related know-how) owned or controlled by Mayo that exist as of the Effective Date that Company would need to practice the license under Section 2.01. In the event any such patents or patent
applications (and any related know-how) do exist and Company obtains a license pursuant to this Section 2.02, then Mayo agrees that the Earned Royalties payable by Company to Mayo hereunder shall be
reduced by the actual payments made by Company to Mayo for such additional licensed technology from Mayo, and such reduction shall not be subject to any floor on Earned Royalties otherwise payable to Mayo under Section 3.03. 

2.03    ACCESS TO KNOW-HOW. Promptly after the Effective Date, Mayo
shall transfer to Company all Know-How existing as of the Effective Date. For a period of [***] years following the Effective Date, Mayo shall allow Company reasonable access to key Mayo personnel (based on
their availability), for consultation and technical assistance on the transfer of Know-How, at no additional cost or expense to Company. 

2.04    SUBLICENSE TO MAYO. 

(a)    Subject to the terms and conditions of this Agreement, Company hereby grants Mayo the right to make,
use and sell Licensed Products within Mayo’s and its Affiliates’ clinics and hospitals, but not to (i) provide or transfer such Licensed Products to any third party, or (ii) use such Licensed Products for patients that are not
Mayo Patients, as further set forth in Section 2.05 (Mayo Activities). The rights granted by this Section 2.04(a) shall be subject to Section 2.05. In consideration of the rights granted to Mayo under this Section 2.04, Mayo
shall pay to Company [***] percent ([***]%) of the Net Sales (as such term is applied mutatis mutandis to Mayo and its Affiliates) of each Licensed Product used or sold within Mayo’s and its Affiliates’ clinics and hospitals. 

(b)    Mayo acknowledges that Company has engaged in research, discovery and validation activities using
Mayo data and algorithms after the term of the 2009 Agreement. Company will provide to Mayo data and algorithms and all improvements thereof sufficient for Mayo to independently implement, validate and perform the most current (at the time Mayo
chooses to implement or perform such test) test developed by Company, its Affiliates, or Sublicensees, provided that such test has the same clinical claim as the tests developed by Company as of the Effective Date. If requested by Mayo,
Company will provide Mayo bioinformatics analysis services for Licensed Products following the first successful CLIA inspection of a Company laboratory, and provided that Mayo offers Licensed Products using the same assay technology platform as
Company. Such bioinformatics analysis services provided by Company to Mayo for the first [***] tests in each calendar year will be at no cost to 

  
 5 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 Mayo, except that Mayo shall be responsible for any third party royalties or license fees
resulting from any such services provided by Company, and all services provided by Company in any calendar year beyond the first [***] tests. All costs associated with creating customer interfaces between Company bioinformatics analysis and Mayo
laboratory information systems are not included in such no-cost services provided by Company to Mayo under this Section 2.04(b), and such costs will be reimbursed by Mayo, if required, in a separate time
and materials agreement consistent with other third party laboratory information system customization agreements. In the event: (i) Company manufactures (or has manufactured) and sells (or licenses others to sell)
FDA-cleared in vitro diagnostic kits based on Licensed Products (a “Kit”), and (ii) Mayo procures such Kits from Company, its Affiliate, reseller or distributor, then Mayo shall not be
required to pay a royalty to Company for each test performed by Mayo using such Kit. 
 2.05    MAYO ACTIVITIES. 

(a)    Subject to Section 2.05(b), Mayo through Mayo Medical Laboratories or any of Mayo’s other
Affiliates (collectively, “MML”) has the right to make and use Licensed Products within Mayo’s and its Affiliates’ clinics and hospitals (“Mayo Patients”), provided that, until the earlier of
(i) August 31, 2015, or (ii) before Company has established Medicare payment specific to Licensed Products through positive coverage decision by the Palmetto GBA MolDx program or any other applicable Medicare Administrative Contractor
program (such program, “MAC Program”), Mayo shall not seek reimbursement or contractual payments for any Licensed Products without prior written consent of Company in connection therewith. 

(b)    Mayo through MML or otherwise, shall not: (i) transfer any Licensed Products to any third
party; or (ii) perform services as defined below in 2.05 (d) for any patient at any hospital or clinic that is not part of Mayo or one of its Affiliates, provided that: (A) in the event Company manufactures (or has
manufactured) and sells (or licenses others to sell) a Kit, Mayo may purchase such Kit from Company or its Affiliates, resellers or distributors, and use such Kits to perform tests for such third parties; and (B) Company and Mayo may elect
to negotiate in good faith a separate contract services agreement under which Mayo would take orders for Licensed Products on behalf of Company, or refer such orders to Company as part of contracted services provided by Company for such third
parties (the “Contract Services Agreement”) as further set forth in Sections 2.05(c) and 2.05(d) below. 

(c)    Mayo Referral and Contract Services Agreement. Any Contract Services Agreement entered into
between Company and Mayo under Section 2.05(b) will include, at Mayo’s request, terms and conditions under which (i) the Company would perform RNA analysis and bioinformatics for a flat fee per test, indexed to be equal to the
Medicare reimbursement rate for Licensed Products in the same year of sale, and (ii) Mayo would have the right to manage specimen logistics, perform histology and tissue micro-dissection, and develop with Company
co-branded test reports. 

(d)    Quality & Turnaround Time. Company shall obtain CLIA certification by
[***], CAP accreditation by [***], and approval by the New York State Department of Health (or demonstration that Company has met the guidelines required by the New York State for such approval) by [***], for: (1) its laboratory providing
services, to the extent services include a Licensed Product (“Services”), and (2) any laboratory it licenses to perform the services on its behalf. Upon obtaining any of the foregoing approvals, Company shall maintain such
approvals for the remainder 

  
 6 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 of the applicable Royalty Term. Failure to obtain and thereafter maintain such approvals
will automatically suspend Mayo’s restriction on providing such services under Section 2.05(b)(ii), for the duration of the lapse and for [***] days following re-approval. In the event of [***] such
lapses to occur in a [***] month period, Mayo shall have the option upon written notice to convert the license granted to Company under Section 2.01 to a co-exclusive license, with Company retaining all
sublicensing rights. Company shall provide Mayo notice of approvals under this Section 2.05(d) and loss of such approvals within [***] business days of the occurrence. Company shall maintain a quarterly average turn-around time of [***] days or
less (from specimen arrival) for all Licensed Products (regardless of whether the test is performed for Mayo or another party). Company shall provide Mayo quarterly reports regarding its average turnaround times within [***] days of the end of the
applicable quarter. If Company fails to meet such turn-around time requirements for two (2) quarters in any given year, Mayo shall have the option upon written notice to convert the license granted to Company under Section 2.01 to a co-exclusive license, with Company retaining all sublicensing rights. 

2.06    RESERVATION OF RIGHTS. All rights herein are subject to: (a) the rights and obligations to and
requirements of the U.S. government, if any have arisen or may arise, regarding the IP Rights, including as set forth in 35 U.S.C. §§200 et al., 37 C.F.R. Part 401 et al. (“Bayh-Dole Act”); and (b) Mayo’s and its
Affiliates’ reserved, irrevocable right to practice and have practiced the IP Rights solely in connection with Mayo’s and its Affiliates’ non-commercial educational and research programs.
Company agrees to comply with the provisions of the Bayh-Dole Act, including promptly providing to Mayo with information requested to enable Mayo to meet its compliance requirements and substantially manufacturing Licensed Product in the U.S. (to
the extent such manufacturing requirement is applicable to Company and has not been waived). 
 2.07    NO
OTHER RIGHTS GRANTED. Except as expressly stated herein, this Agreement does not grant to either party any right, title or interest in or to any tangible or intangible property right of the other party or its Affiliates, including any
improvements thereon. All such rights, titles and interests are expressly reserved by each party and the other party agrees that in no event will this Agreement be construed as a sale, an assignment, or an implied license by such party or its
Affiliates to such other party of any such tangible or intangible property rights. 
 Article 3.00 – Royalties & Payments

 3.01    UPFRONT PAYMENTS. In consideration of the licenses and rights granted herein, Company will
provide Mayo the following: 
 (a)    A one-time upfront payment
of one hundred thousand dollars ($100,000) within thirty (30) days after the Effective Date. 

(b)    A warrant for one million six-hundred and seventy-five
thousand (1,675,000) shares of Company’s common stock with a strike price of $1.14 and a ten (10) year term starting on the Effective Date. 

3.02    MAINTENANCE FEE. Company will pay Mayo an annual maintenance fee of fifteen thousand dollars
($15,000), with the first of such payment due on [***], and Company’s obligation to pay such annual maintenance fee shall terminate upon the first commercial sale 

  
 7 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 of a Licensed Product. Company will pay each such annual maintenance fee within thirty
(30) days of receipt of the applicable invoice from Mayo. This annual maintenance fee is nonrefundable and is not creditable against any future Earned Royalties otherwise due under this Agreement. 

3.03    EARNED ROYALTIES. Subject to Section 3.04, Company will make nonrefundable and non-creditable earned royalty payments to Mayo in an amount equal to [***] percent ([***]%) of Net Sales of Licensed Products (“Earned Royalties”). The Earned Royalties are payable as described in
Section 4.01, and are payable on a Licensed Product-by-Licensed Product and
country-by-country basis from the first commercial sale of such Licensed Product in such country until the end of the Royalty Term for such Licensed Product in such
country. Licensed Products transferred to Mayo or its Affiliates are not considered transfers for purposes of determining Net Sales or for calculating Earned Royalties. No Earned Royalties are due to Mayo on Licensed Products sold or transferred to
Mayo or Mayo’s Affiliates. 
 3.04    ROYALTY STACKING. Earned Royalties shall be reduced in
accordance with this Section 3.04 if the Licensed Product incorporates another technology licensed by Company or its Affiliate from a third party. In such case of royalty stacking, the Earned Royalties payable by Company to Mayo shall be
reduced by [***] percent ([***]%) of the actual payments made by Company or its Affiliate to such third party for the non-Mayo licensed technology; provided, however, that the Earned Royalties
payable to Mayo will not be reduced to a level below [***] percent ([***]%) of the rate otherwise payable to Mayo under Section 3.03. 

3.05    SALES MILESTONES. Company will make the following one-time,
nonrefundable, non-creditable sales milestone payment to Mayo when the cumulative Net Sales of all Licensed Products in the Territory first reach the amount specified below. Company will pay to Mayo such sales
milestone payment within thirty (30) days after the calendar quarter in which such event is achieved. For clarity, the below sales milestone payment shall be made only once for all Licensed Products (regardless of the number of separate
Licensed Products developed or commercialized under this Agreement) during the Term for the first occurrence of the milestone event with respect to such Licensed Products. 
  

			
	 Sales Milestone Event
	  	 Milestone Payment

	 Upon cumulative Net Sales of all Licensed

Products equaling [***] dollars ($[***])
	  	 Two hundred fifty thousand dollars ($250,000)

 3.06    SUBLICENSE INCOME. Company will, in accordance with
Section 4.01, make payment to Mayo in an amount equal to [***] percent ([***]%) of Sublicense Income. 

3.07    PAST PATENT COSTS. Company shall reimburse Mayo for all documented,
out-of-pocket patent costs associated with IP Rights actually incurred by Mayo prior to the Effective Date, in an amount not to exceed [***] dollars ($[***]). Company
will pay such patent costs within thirty (30) days of receipt of an invoice and supporting documents from Mayo. 

3.08    TAXES. Company is responsible for all taxes, duties, import deposits, assessments, and other
governmental charges, however designated, which are now or hereafter imposed by any authority on Company: (a) by reason of the payment of any amounts by Company to Mayo under this Agreement; (b) based on Company’s use of the IP
Rights; or (c) related to use, sale or import of the Licensed Product, except for any transfer of Licensed Product to Mayo or its Affiliates as contemplated hereunder. Any 

  
 8 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 withholding taxes that Company is required by law to withhold on remittance of the royalty
payments shall be paid forthwith to Mayo in an amount which shall result in the net amount being received by Mayo being equal to the amount which would have been received by Mayo had no such deduction or withholding been made. Each party will
obtain, or assist the other party in obtaining, any tax reduction (including avoidance of double taxation), tax refund or tax exemption available to the parties by treaty or otherwise. 

3.09    U.S. CURRENCY. All payments to Mayo under this Agreement will be made by draft drawn on a U.S. bank,
and payable in U.S. dollars. In the event that conversion from foreign currency is required in calculating a payment under this Agreement, the exchange rate used shall be the Interbank rate quoted by Citibank at the end of the last business day of
the calendar quarter in which the payment accrued. 
 3.10    OVERDUE PAYMENTS. If overdue, the payments
due under this Agreement shall bear interest until paid at a rate of [***]. 
 Article 4.00 – Accounting and Reports 

4.01    REPORTS AND PAYMENT. After the first commercial sale of a Licensed Product or the first grant of a
sublicense to a Sublicensee, whichever is earlier, Company will deliver to Mayo on or before the following dates: 1 June and 1 December, a written report setting forth the Net Sales in the preceding six months and any payments due from
Sublicense Income. If no Licensed Product transfers have occurred and no other amounts are due to Mayo, Company will submit a report so stating. Each such report will be accompanied by the payment of all amounts due for such period. 

4.02    ACCOUNTING. Company will keep complete, continuous, true, and accurate books of accounts and records
sufficient to support and verify the calculation of Net Sales, all royalties and any other amount that are due and payable to Mayo under this Agreement. Such books and records will be kept at Company’s principal place of business for at least
three (3) years after the end of the calendar year to which they pertain, and will be open for inspection during regular business hours as agreed upon by the parties (not more than once per calendar year) by an authorized representative of Mayo
for verification of royalty statements or compliance with other financial aspects of this Agreement. The Mayo representative will be a person or firm reasonably acceptable to Company, and such Mayo representative shall enter into an acceptable
confidentiality agreement with Company to treat as confidential all relevant matters of the audit. In the event such audit reveals a discrepancy (either an underpayment or overpayment by Company) then the appropriate party will, within thirty
(30) days, pay the other party the amount of such discrepancy. Mayo shall bear all costs in conducting any audit; provided, however, in the event the audit reveals an underpayment by Company of more than [***] percent ([***]%) of
the amount due, Company will reimburse Mayo for its out-of-pocket costs for such audit. 

Article 5.00 – Diligence 

5.01    DILIGENCE. Company will use commercially reasonable efforts to bring the Licensed Product to market
in the Field within the Territory, including obtaining Medicare reimbursement for the Licensed Product. The following sets forth Company’s projected timeline, as of the Effective Date, with respect to development and commercialization of the
Licensed Product. The Parties agree that such projections 

  
 9 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 have been provided by Company in good faith, but the completion dates are subject to change
due to factors outside the reasonable control of Company, and as such Company’s inability to meet the following completion dates shall not constitute a material breach of Company’s obligations hereunder. 

 

			
	 [***]
	 	[***]
	
[***]
	 	[***]
	
[***]
	 	[***]
	
[***]
	 	[***]

 Article 6.00 – Intellectual Property Management 

6.01    CONTROL. Company shall have the first right to prepare, file, prosecute, maintain and enforce IP
Rights with prior advice and comment from Mayo. In the event of a disagreement between Company and Mayo regarding the IP Rights, Company shall make the decision. Company shall pay all costs and expenses associated with the filing, prosecution and
maintenance, enforcement and defense of the IP Rights. In the event that Company desires not to continue prosecuting, maintaining, enforcing and/or defending a Valid Claim within the IP Rights, it shall provide Mayo reasonable notice (not less than
thirty (30) days) to such effect. Mayo shall then have the right, but not the obligation, to assume control of the prosecution, maintenance, enforcement and/or defense of such claim within the IP Rights. Under such circumstances, Mayo shall
have the right, without obligation, to immediately terminate Company’s license to such Valid Claim under this Agreement. Mayo shall have sole control over the protection, defense, enforcement, maintenance, abandonment and other handling of the Know-How. 
 6.02    PATENT TERM EXTENSION. Company shall consult with
Mayo in selecting the patent covering each Licensed Product for term extension or supplementary protection certificate in accordance with the applicable laws of any country, provided that Company shall make the final decision. Mayo agrees to execute
any documents and to take any additional actions as Company may reasonably request in connection therewith. 

6.03    PATENT MARKING. To the extent commercially feasible and required by applicable law, Company will
mark all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent within the IP Rights that covers such Licensed Product(s). Any such marking will be in conformance with the patent laws and other
laws of the country of manufacture or sale. 
 6.04    ENFORCEMENT. Each party shall promptly inform the
other party in writing of any alleged or threatened infringement of any of the IP Rights or Know-How and provide the other party with any available evidence of such infringement. Company shall have the first
right, but not the obligation, to enforce the IP Rights. Company will keep Mayo reasonably informed and will give Mayo the opportunity to advise and comment. Mayo shall reasonably cooperate in any such action at Company’s request and expense,
but shall not be required to join such action unless it has agreed to do so in writing prior to 

  
 10 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 commencement thereof, or unless otherwise required by applicable laws in order for Company
to pursue such action. Any recovery or damages from a suit or settlement shall be allocated as follows: first, all of Company’s costs and expenses associated with such suit or settlement shall be reimbursed, and second, any remaining amount
shall be retained by Company, but subject to payment of Earned Royalties to Mayo in accordance with Section 3.03 with respect to that portion of the recovery or damages directly attributable to sales of Licensed Products. In the event that
Company desires not to enforce and/or defend the IP Rights, it shall provide Mayo reasonable notice to such effect. In such event, or in the event that Company does not enforce and/or defend the IP Rights in a reasonable period of time after
receiving notice from Mayo of potential infringement of IP rights by a third party, Mayo shall have the right, without obligation, to assume control of the enforcement and/or defense of such claim within the IP Rights. 

Article 7.00 – Use of Name 

7.01    USE OF NAME AND LOGO. Neither Party shall use the name, trademark, trade name or logo of the other
Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written consent of such other Party, except as may be required
by law. Each party may withhold such consent in its absolute discretion. For clarity, Company will not use for publicity, promotion, or otherwise, any logo, name, trade name, service mark, or trademark of Mayo or its Affiliates, including, but not
limited to, the terms “Mayo®,” “Mayo Clinic®,” and the triple shield Mayo logo, or any simulation, abbreviation, or
adaptation of the same. With regard to the use of Mayo’s name, all requests for approval pursuant to this Section 7.01 must be submitted to the Mayo Clinic Public Affairs Business Relations Group, at the following e-mail address: PublicAffairsBR@Mayo.edu at least five (5) business days prior to the date on which a response is needed. 

Article 8.00 – Confidentiality 

8.01    TREATMENT OF CONFIDENTIAL INFORMATION. Subject to the other provisions of this Article 8: 

(a)    All Confidential Information disclosed by a party or its Affiliates under this Agreement will be
maintained in confidence and otherwise safeguarded by the receiving party and its Affiliates, in the same manner and with the same protection as such receiving party maintains its own confidential information. 

(b)    The receiving party may only use any such Confidential Information for the purposes of performing
its obligations or exercising its rights under this Agreement. 
 (c)    The receiving party may
disclose Confidential Information of the other party only to: (i) its Affiliates and Sublicensees, and (ii) employees, directors, agents, contractors, consultants and advisers of the receiving party and its Affiliates and Sublicensees, in
each case to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement; provided, however, that such persons are bound to maintain the confidentiality of such Confidential
Information in a manner consistent with the confidentiality provisions of this Agreement. 

  
 11 

 8.02    RIGHT TO DISCLOSE. Notwithstanding the obligations
set forth in Section 8.01, a party may disclose the other party’s Confidential Information: 

(a)    To the extent it is reasonably necessary or appropriate to fulfill the party’s obligations or
exercise its rights under this Agreement, including (i) for the filing or prosecuting of IP Rights as contemplated hereunder, (ii) in connection with regulatory filings for the Licensed Product, or (iii) for prosecuting or defending
litigation as contemplated by this Agreement. 
 (b)    If such party is required by applicable law,
regulation or valid court order to disclose any of such other party’s Confidential Information, provided that such party: (i) promptly notifies the other party; and (ii) reasonably assists the other party to obtain a protective order
or other remedy of such other party’s election and at such other party’s expense. 

8.03    CONFIDENTIALITY OF AGREEMENTS. Except as otherwise required by law, the specific terms and
conditions of this Agreement shall be the parties’ Confidential Information. However, the existence of this Agreement and its Field will not be Confidential Information, and the parties may state that Company is licensed by Mayo under the IP
Rights. 
 Article 9.00 – Warranties, Representations, Disclaimers and Indemnification 

9.01    REPRESENTATIONS AND WARRANTIES. 

Company warrants and represents to Mayo as of the Effective Date that: 

 

	 	(i)	 it will maintain insurance coverage as set forth in Section 9.03 and that such insurance coverage
sufficiently covers the Mayo Indemnitees; 

  

	 	(ii)	 the execution and delivery of this Agreement has been duly authorized and no further approval, corporate or
otherwise, is required in order to execute this binding Agreement; 

  

	 	(iii)	 it shall comply, and require its Affiliates and Sublicensees to comply, with all applicable international,
national, and state laws, ordinances and regulations in its performance under this Agreement; and 

  

	 	(iv)	 its rights and obligations under this Agreement do not conflict with any contractual obligation or court or
administrative order by which it is bound. 

  

	 	(b)	 Mayo warrants and represents to Company as of the Effective Date that: 

 

	 	(i)	 it has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest
in the IP Rights in a manner that is inconsistent with the exclusive license granted to Company under Section 2.01; 

  

	 	(ii)	 it will maintain insurance coverage as set forth in Section 9.03 and that such insurance coverage
sufficiently covers the Company Indemnitees; 

  
 12 

	 	(iii)	 the execution and delivery of this Agreement has been duly authorized and no further approval, corporate or
otherwise, is required in order to execute this binding Agreement; 

  

	 	(iv)	 it shall comply, and require its Affiliates to comply, with all applicable international, national, and
state laws, ordinances and regulations in its performance under this Agreement; and 

  

	 	(v)	 its rights and obligations under this Agreement do not conflict with any contractual obligation or court or
administrative order by which it is bound. 

 9.02    DISCLAIMERS; LIMITATION OF
LIABILITY. 
 (a)    EXCEPT AS EXPLICITLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS TO THE
OTHER PARTY ANY EXPRESS OR IMPLIED WARRANTY, INCLUDING WARRANTIES OF NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ARISING OUT OF ITS PERFORMANCE OR ATTEMPTED DEVELOPMENT OF ANY
PRODUCT OR METHODS HEREUNDER. 
 (b)    ANY INFORMATION, INCLUDING
KNOW-HOW, ANY IP RIGHTS PROVIDED OR LICENSED UNDER THIS AGREEMENT ARE PROVIDED “AS IS,” “WITH ALL FAULTS,” AND “WITH ALL DEFECTS,” AND COMPANY EXPRESSLY WAIVES ALL RIGHTS TO MAKE
ANY CLAIM WHATSOEVER AGAINST MAYO FOR MISREPRESENTATION OR FOR BREACH OF PROMISE, GUARANTEE, OR WARRANTY OF ANY KIND RELATING TO ANY PRODUCTS OR SERVICES DEVELOPED HEREUNDER. 

(c)    NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR
CONSEQUENTIAL DAMAGES (REGARDLESS OF THE THEORY OF LIABILITY) RESULTING FROM OR IN ANY WAY RELATED TO THE BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT IN THE EVENT OF MAYO’S BREACH OF ITS
OBLIGATIONS UNDER SECTION 2.05, WHEREIN MAYO SHALL BE LIABLE TO COMPANY, BUT ONLY FOR QUANTIFIABLE INDIRECT, INCIDENTAL AND CONSEQUENTIAL DAMAGES, AND NOT FOR ANY SPECIAL OR PUNITIVE DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION
9.02 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE THEINDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY WITH RESPECT TO ANY LIABILITY TO A THIRD PARTY UNDER SECTION 9.03., PROVIDED HOWEVER IN THE EVENT MAYO DOES NOT PERFORM TESTS FOR THIRD PARTIES
AS CONTEMPLATED UNDER SECTION 2.05 (b), IN NO EVENT SHALL MAYO’S TOTAL LIABILITY EXCEED THE TOTAL AMOUNT OF ROYALTIES THAT HAVE ACTUALLY BEEN PAID TO MAYO BY COMPANY AS OF THE DATE OF FILING AN ACTION AGAINST MAYO THAT RESULTS IN THE SETTLEMENT
OR AWARD OF DAMAGES TO COMPANY. 

  
 13 

 9.03    INDEMNIFICATION AND INSURANCE. 

(a)    Company will defend, indemnify, and hold harmless Mayo, Mayo’s Affiliates and their respective
trustees, officers, agents and employees (“Mayo Indemnitees”) from any and all losses, costs, expenses, damages and liabilities (including attorneys’ fees, court costs and other expenses of litigation) (“Losses”) based on
third party claims arising out of or connected with: (i) Company’s practice or exercise of any rights granted to it hereunder by Mayo; (ii) the research, development, and commercialization of Licensed Products by Company;
(iii) the negligence or willful misconduct of Company; and (iv) Company’s material breach of its obligations, representations or warranties under this Agreement; except in each case to the extent that such Losses arise in whole or in
part from (X) the gross negligence or willful misconduct of any Mayo Indemnitee, or (Y) the material breach by Mayo of any obligations, representations, or warranties made by Mayo in this Agreement. 

(b)    Mayo will defend, indemnify, and hold harmless Company, Company’s Affiliates and their
respective trustees, officers, agents and employees (“Company Indemnitees”) from any and all Losses based on third party claims arising out of or connected with: (i) Mayo’s practice or exercise of any rights granted to it
hereunder by Company; (ii) the making and use of Licensed Products by Mayo or its Affiliates pursuant to rights granted under Section 2.04 and Mayo’s activities under Section 2.05; (iii) the negligence or willful misconduct of
Mayo; and (iv) Mayo’s material breach of its obligations, representations or warranties under this Agreement; except to the extent that such Losses arise in whole or in part from (X) the gross negligence or willful misconduct of any
Company Indemnitee, or (Y) the material breach by Company of any obligations, representations, or warranties made by Company in this Agreement. 

(c)    If either party is seeking indemnification under Section 9.03(a) or 9.02(b) (the
“Indemnified Party”), it shall inform the other party (the “Indemnifying Party”) of the claim giving rise to the obligation to indemnify as soon as reasonably practicable after receiving notice of the claim. The Indemnifying
Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the
Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim that has been
assumed by the Indemnifying Party. Neither party shall have the obligation to indemnify the other Party in connection with any settlement made without the Indemnified Party’s written consent, which consent shall not be unreasonably withheld or
delayed. 
 (d)    Each party will procure and maintain insurance, including product liability
insurance, adequate to cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated at all times during which any Licensed Product is being clinically tested in human subjects or commercially
distributed or sold by such party and for the three (3) year period thereafter. Each party shall provide the other party with written evidence of such insurance upon request. 

9.04    PROHIBITION AGAINST INCONSISTENT STATEMENTS. Neither party shall make any statements,
representations or warranties, or accept any liabilities or responsibilities whatsoever which are inconsistent with any disclaimer or limitation included in this Article 9 or any other provision of this Agreement. 

  
 14 

 Article 10.00 – Term and Termination 

10.01    TERM. Unless earlier terminated pursuant to this Article 10, this Agreement will expire at the end
of the Term. Upon expiration of the Term, the license granted to Company pursuant to Section 2.01 shall become a fully paid-up, perpetual, irrevocable license. 

10.02    TERMINATION FOR CONVENIENCE. At any time during the Term, Company may terminate this Agreement, at
its sole discretion and for any reason or no reason, by providing ninety (90) days written notice of termination to Mayo. 

10.03    TERMINATION FOR BREACH. If either party believes that the other is in breach of its material
obligations hereunder, then the non-breaching party may deliver written notice of such breach to the other party. For all breaches other than a failure to make a payment set forth in this Agreement, the
allegedly breaching party shall have ninety (90) days to cure such breach from the receipt of the notice. For any breach arising from a failure to make a payment set forth in this Agreement, the allegedly breaching party shall have sixty
(60) days from the receipt of the notice to cure such breach. If the party receiving notice of breach fails to cure that breach within the applicable period set forth above, then the party originally delivering the notice of breach may
terminate this Agreement on written notice of termination, provided that, if the party receiving notice of breach (other than a payment breach) in good faith disputes such allegation of breach under Section 11.04, then this Agreement may not be
terminated unless and until (a) the dispute has been resolved in favor of the party originally delivering the notice of breach; and (b) the breach is not cured within thirty (30) days thereafter, but in no event shall such termination
abeyance last longer than 180 days from the date of notice of a good faith dispute. 
 10.04    TERMINATION
FOR SUIT. Mayo may terminate this Agreement upon written notice if Company, its Affiliate or any Sublicensee, individually or in association with any other person or entity, commences a legal action challenging the validity, enforceability or
scope of any IP Rights. Notwithstanding the foregoing, Mayo shall not terminate this Agreement if: 

(a)    such legal action is not made directly by Company or its Affiliates but is made by a third party
(including a Sublicensee), 
 (b)    in the event such third party is a Sublicensee, Company has
incorporated specific language in its sublicense agreement that permits the Company to terminate all rights granted to such Sublicensee, including, but not limited to any sublicense rights to use the IP Rights and/or freedom to operate under IP
Rights, upon its initiation of such legal action, and 
 (c)    in the event the Company terminates such
sublicense and such Sublicensee does not withdraw such legal action, then Company fully cooperates with Mayo in defending the validity, enforceability or scope of such IP Rights involved in such legal action. Terms of such enforcement action will be
governed Section 6.04. 
 10.05    SURVIVAL. The termination or expiration of this Agreement does not
relieve either party of its rights and obligations that have previously accrued. Upon termination or expiration of this Agreement, each party shall return or certify destruction (at the other party’s election) all Confidential Information of
the other party. Rights and obligations that by their nature prescribe continuing rights and obligations shall survive the termination or expiration of this Agreement, including Sections 4.02, 9.02, 9.03, 10.05 and Articles 7, 8 and 11. Company, its
Affiliates and its Sublicensees shall provide an accounting for and 

  
 15 

 pay, within thirty (30) days after the effective date of termination or expiration, of
all amounts due hereunder. 
 Article 11.00 – General Provisions 

11.01    ASSIGNMENT AND TRANSFER. This Agreement may not be assigned or otherwise transferred, nor may any
right or obligation hereunder be assigned or transferred, by either party without the prior written consent of the other party, such consent not to be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, either party may,
without consent of the other party, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of such party or to its third party
successor-in-interest in connection with the sale of all or substantially all of its business to which this Agreement relates, whether in connection with a merger, sale
of stock, sale of assets, acquisition or similar transaction. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. Any assignment, delegation or transfer in contravention of this Section 11.01 is
null and void. 
 11.02    WAIVER. No part of this Agreement may be waived except by the further written
agreement of the party granting such waiver. Forbearance in any form from demanding the performance of a duty owed under this Agreement is not a waiver of that duty. Until complete performance of a duty owed under this Agreement is accomplished, the
party to which that duty is owed may invoke any remedy under this Agreement or under law, despite its past forbearance in demanding performance of that duty. 

11.03    GOVERNING LAW AND JURISDICTION. The terms and conditions of this Agreement, as well as all disputes
arising under or relating to this Agreement, shall be governed by New York law, specifically excluding its choice-of-law principles, except that the interpretation,
validity and enforceability of the IP Rights will be governed by the patent laws of the country in which the patent application is pending or issued. 

11.04    DISPUTE RESOLUTION. The parties shall negotiate in good faith and use reasonable efforts to settle
any dispute, controversy or claim arising from or related to this Agreement of the breach thereof. If the parties do not fully settle, and a party wishes to pursue the matter, each such dispute, controversy or claim shall be finally resolved by
binding arbitration (an “Arbitration”) administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules then in effect, and judgment on the Arbitration award
may be entered in any court having jurisdiction thereof. An Arbitration shall be conducted by one (1) arbitrator with experience in the molecular diagnostic or biotechnology business mutually agreed upon the parties. All proceedings and
communications of such arbitration shall be in English. Either party may apply to the arbitrator for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either party also may, without waiving
any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that party pending the arbitration award. The arbitrator shall have no authority to award
punitive, exemplary or any other type of damages not measured by a party’s compensatory damages. Each party shall bear an equal share of the arbitrator’s fees and any administrative fees of each Arbitration. The proceedings and decision of
the arbitrator in any Arbitration under this Section 11.04 shall be confidential. 
 11.05    HEADINGS.
The headings of articles and sections used in this document are for convenience of 

  
 16 

 reference only. 

11.06    NOTICES. Any notice required to be given under this Agreement is properly provided if in writing
and sent to the party at its address or facsimile number below, or as otherwise designated by the party in accordance with this provision, and duly given or made: (a) on the date delivered in person; (b) on the date transmitted by
facsimile, if confirmation is received; (c) three (3) days after deposit in the mail if sent by certified U.S. mail postage prepaid, return receipt requested; and (d) one (1) day after deposit with a nationally recognized overnight carrier
service with charges prepaid. 
 If to Mayo: 

Mayo Foundation for Medical Education and Research 

Mayo Clinic Ventures – BB4 

200 First Street SW 

Rochester, Minnesota 55905-0001 

Attn: Manu Nair or Operations 

Phone: 

Facsimile: 

Email: 

Fed Tax ID: 
 If
to Company: 
 GenomeDx Biosciences, Inc. 

311 Water Street, 4th Floor 

Vancouver, B.C., Canada, V6B 1B8 

Attn: Chief Financial Officer 

Facsimile: 

11.07    LIMITATION OF RIGHTS CREATED. This Agreement is personal to the parties and shall be binding on and
inure to the sole benefit of the parties and their permitted successors and assigns and shall not be construed as conferring any rights to any third party. Specifically, no interests are intended to be created for any customer, patient, research
subjects, or other persons (or their relatives, heirs, dependents, or personal representatives) by or upon whom the Licensed Products may be used. 

11.08    INDEPENDENT CONTRACTORS. Each party shall act solely as an independent contractor, and nothing in
this Agreement shall be construed to give either party the power or authority to act for, bind, or commit the other party in any way. Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture
partners between the parties. 
 11.09    ENTIRE AGREEMENT. This Agreement, including the Exhibits hereto,
sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes all
prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written,
between the Parties other 

  
 17 

 than as are set forth in this Agreement. 

11.10    SEVERABILITY. If any terms or conditions of this Agreement are or become in conflict with the laws,
regulations or court order of any jurisdiction or any governmental entity having jurisdiction over the parties or this Agreement, those terms and conditions shall be deemed automatically deleted in such jurisdiction(s) only, and the remaining terms
and conditions of this Agreement shall remain in full force and effect. If such a deletion is not so allowed in a given jurisdiction or if such a deletion leaves terms and conditions thereby made clearly illogical or inappropriate in effect,
the parties agree to substitute new terms and conditions as similar in effect to the present terms of this Agreement as may be allowed under the applicable laws, regulations or court order of such jurisdiction. The parties desire the terms and
conditions herein to be valid and enforced to the maximum extent not prohibited by law, regulation or court order in a given jurisdiction. 

11.11    CHANGES TO AGREEMENT. No terms or conditions of this Agreement may be changed except in writing,
through another document signed by both parties, and expressly referencing this Agreement. 

11.12    CONSTRUCTION. Each party acknowledges that it was provided an opportunity to seek advice of counsel
and as such this Agreement shall not be construed for or against either party. 
 11.13    REGISTRATION OF
LICENSES. Company will register and give required notice concerning this Agreement, at its expense, in each country in the Territory where (a) it is developing or commercializing the Licensed Product and (b) an obligation under
applicable law exists to so register or give notice. 
 11.14    EXPORT CONTROL. Mayo is subject to U.S.
laws and regulations controlling the export of technical data, computer software, laboratory prototypes, and other commodities that may require a license from the applicable agency of the United States government and/or may require written
assurances by Company that it will not export data or commodities to certain foreign countries without prior approval of such agency. Mayo neither represents that a license is required, nor that, if required, it will be issued. 

11.15    COUNTERPARTS. This Agreement may be executed in one (1) or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [Signatures on next page] 

  
 18 

 IN WITNESS WHEREOF, the parties
have executed this Agreement by their duly authorized officers as of the Effective Date. 
 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: 

 

	
	 Signed: /s/
Daniel D. Estes                                     
                 

	
Printed Name: Daniel D. Estes          
                                      

	
Title: Assistant Treasurer             
                                         
   

	
Date: 2-18-2013    
                                         
                          

 GENOMEDX BIOSCIENCES, INC.: 
  

	
	 Signed: /s/ Andy
Katz                                         
                     

	
Printed Name: Andy Katz, PhD               
                                

	
Title: Vice President, Operations & CBO           
                     

	
Date: 11 FEB 2013                 
                                         
         

  
 19 

 EXHIBIT A 

IP Rights 
 [***]

  
 20 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 EXHIBIT B 

Know-How 

[***] 

  
 21 

[***]=CERTAIN CONFIDENTIAL INFORMATION OMITTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]